Zafirlukast attenuates advanced glycation end-products (AGEs)-induced degradation of articular extracellular matrix (ECM)

Int Immunopharmacol. 2019 Mar:68:68-73. doi: 10.1016/j.intimp.2018.12.056. Epub 2019 Jan 4.

Abstract

Zafirlukast, a leukotriene receptor antagonist, has been shown to exert a wide range of effects including anti-asthmatic, anti-inflammatory and oral anti-bacterial. Osteoarthritis is one of the most prevalent age-related public health burdens in the modern world. In the present study, we applied zafirlukast in the treatment of human primary chondrocytes and found that it exerts potent anti-osteoarthritic effects. Zafirlukast inhibited AGEs-induced degradation of the articular extracellular matrix by suppressing expression of MMPs, ADAMTS, NOX-4, generation of ROS, and activation of NF-κB via the IκBα/JNK/AP-1 pathway through targeted inhibition of CysLTR1. These findings suggest that zafirlukast possesses a protective effect against AGEs- induced damage and dysfunction in human chondrocytes.

Keywords: AGEs; Articular ECM; NF-κB; NOX-4; Osteoarthritis; Zafirlukast.

MeSH terms

  • Anti-Inflammatory Agents / pharmacology*
  • Cells, Cultured
  • Chondrocytes / drug effects*
  • Chondrocytes / physiology
  • Extracellular Matrix / drug effects*
  • Extracellular Matrix / physiology
  • Glycation End Products, Advanced / physiology*
  • Humans
  • Indoles
  • Leukotriene Antagonists / pharmacology*
  • Phenylcarbamates
  • Reactive Oxygen Species / metabolism
  • Sulfonamides
  • Tosyl Compounds / pharmacology*

Substances

  • Anti-Inflammatory Agents
  • Glycation End Products, Advanced
  • Indoles
  • Leukotriene Antagonists
  • Phenylcarbamates
  • Reactive Oxygen Species
  • Sulfonamides
  • Tosyl Compounds
  • zafirlukast